^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Salivary Gland Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Published date:
03/25/2020
Excerpt:
In addition to NSCLC and colorectal cancer, responses were also observed across a number of other tumor types, including HER2-expressing or HER2-amplified salivary gland cancer, biliary tract cancer, and endometrial cancer, and HER2-mutant nonamplified breast cancer (Fig. 3). In this group, the ORR was 6 of 22 (27.3%) and the median DoR was not reached (95% CI, 3.0–not reached). The median PFS was 11.0 months (95% CI, 2.8–NE; Table 3).
DOI:
10.1158/2159-8290.CD-19-1014
Trial ID:
